University of Chicago Develops Targeted mRNA Nanoparticle System to Prevent Type 1 Diabetes Progression

Scientists at the University of Chicago查看公司主页 have developed a novel nanoparticle-based approach to prevent type 1 diabetes (搜索)搜索该疾病 by delivering mRNA (搜索)搜索该药品 directly to insulin-producing beta cells, enabling them to protect themselves from autoimmune destruction. The research, published in Cell Reports Medicine, demonstrates a fundamentally different strategy from conventional approaches that focus on suppressing the immune system.

The lipid nanoparticle system carries mRNA (搜索)搜索该药品 instructions for PD-L1 (搜索)搜索该靶点, a cell surface protein that helps cells evade immune system attacks. In experiments with both mouse and human beta cells, the nanoparticles successfully reached their targets and triggered PD-L1 expression. The technology also proved effective in a transplant model where human beta cells were implanted into mice.

"In this initial therapeutic proof of concept, we showed that we were able to deliver PD-L1 (搜索)搜索该靶点 mRNA (搜索)搜索该药品 with our nanoparticle system, enable a delay in type 1 diabetes (搜索)搜索该疾病 progression in mice, and also show potential translational relevance within human cells," said Jacob Enriquez, PhD, a postdoctoral scholar at UChicago who led the study.

Novel Targeting Strategy

The research team, led by Enriquez in the laboratory of Raghu Mirmira, MD, PhD, Professor of Medicine, collaborated with Yun Fang, PhD, Professor of Medicine, and Zhengjie Zhou, PhD, formerly at UChicago and now at Temple University查看公司主页. Zhou created the nanoparticle using four lipids that can encapsulate mRNA (搜索)搜索该药品 molecules, employing the same technology used in COVID-19 vaccines.

The team developed two versions of the nanoparticles: one tagged with a peptide to target GLP-1 receptors (搜索)搜索该靶点 on beta cell surfaces—the same receptor targeted by weight loss drugs like Ozempic查看药品详情 and Wegovy查看药品详情—and one without the peptide. During in vitro testing, both versions successfully enriched PD-L1 (搜索)搜索该靶点 expression in mouse and human cells, with the GLP-1 tagged version showing slightly better performance in mice.

Selective Cell Targeting

A key advantage of this approach is its specificity. Both nanoparticle versions can target beta cells without affecting other cell types, thereby avoiding unintended consequences. This precision targeting is crucial for therapeutic applications, as PD-L1 (搜索)搜索该靶点 is often exploited by cancers to evade immune detection, making system-wide PD-L1 enhancement potentially problematic.

"Nanomedicine approaches were central to the clinical success of RNA vaccines," Fang said. "Our conceptual and technological advances establish a strong foundation for extending this paradigm to metabolic diseases through selective targeting of insulin-producing cells and, ultimately, other key cell types involved in type 1 diabetes (搜索)搜索该疾病."

Clinical Implications

The treatment would ideally be administered before full disease onset, while beta cells remain functional, to preserve insulin production capacity. The researchers envision using this platform to deliver other therapeutic molecules and potentially incorporating additional surface peptides to target human beta cell receptors more effectively.

"This is generating a new level of excitement, because now we're thinking about engineering beta cells with the knowledge we've accumulated over the years," said Mirmira, who also serves as Director of the UChicago Diabetes Research and Training Center. "Going forward, it's a promising tool because we can target a specific cell type without harming other cells."

The research represents a significant departure from traditional type 1 diabetes (搜索)搜索该疾病 prevention strategies, which typically focus on suppressing autoimmune responses. Instead, this approach empowers beta cells to defend themselves while maintaining their insulin-producing function.